MedPath

Rapid Orocecal Transit Time and Fermentation in IBS.

Conditions
Oro-cecal Transit Time
Registration Number
NCT03141268
Lead Sponsor
Uppsala University
Brief Summary

Orocecal transit time is studied in individuals with irritable bowel syndrome (IBS) of both the constipation-dominant, diarrhea-dominant, and mixed form using the lactulose hydrogen breath test for orocecal transit time through the gut. Data are compared to those of healthy volunteers. The peak value of fermentation as read by hydrogen levels is captured after passage of the orocecal segment in the colon. Comparison are made between IBS patients and healthy subjects as regards orocecal transit time and peak fermentation in the cecum.

Detailed Description

Patients with IBS of various kind (constipation-dominant, diarrhea-dominant, and mixed form) in large numbers are studied as regards orocecal transit time and compared to healthy controls.

Inclusion criteria: IBS patients 18-80 years old, diagnosis of IBS; exclusion: Severe cardiac, pulmonary, liver or kidney disease, bloody stool After fasting for 12 hours, all subjects ingest 10 grams of lactulose. Hydrogen production, measured as hydrogen concentration in breath, is estimated at 10-minute intervals for a period of 240 minutes. The orocecal transit transit time is measured from ingestion of the lactulose solution until hydrogen peaks to 10 and 20 ppm when passing the ileocecal valve, being fermented by the cecal microflora. Data are compared to those of healthy volunteers.

The peak value of fermentation as read by hydrogen levels (ppm) captured after passage of the ilecocecal valve orocecal valve signifies the gas production of the micro13flora. Comparison are made between IBS patients and healthy subjects as regards orocecal transit time and peak fermentation in the cecum.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Healthy subjects, or IBS patients or either kind (IBS-C, IBS-D, IBS-M), no concomitant medication.
Exclusion Criteria
  • Chronic disease, such cardiac, pulmonary, liver, kidney, endocrinological rheumatological, neurological or psychiatric disease plus, in addition, chronic medication.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Orocecal transit time0-240 minutes

The transit rate of lactulose (foods) through the small intestine

Secondary Outcome Measures
NameTimeMethod
Fermentation of lactulose of the cecal microbiota measured as increase of hydrogen in exhaled breath.0-240 minutes

The rise of hydrogen (beyond 10 and 20 ppm) after lactulose passing the ileo-cecal valve.

Trial Locations

Locations (1)

Uppsala University

🇸🇪

Uppsala, Uppsala County, Sweden

Uppsala University
🇸🇪Uppsala, Uppsala County, Sweden
Per M Hellstrom, MD, Prof
Contact
+46 70 3727423
Per.Hellstrom@medsci.uu.se
Dominic-Luc Webb, PhD
Contact
+46 18 4714721
Dominic-Luc.Webb@medsci.uu.se
Per M Hellström, MD, Prof
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.